Skip to main content

CONEXION ENTRE EL ESTRES DEL RETICULO ENDOPLASMICO Y LA ALFA-SINUCLEOPATIA EN LOS TRASTORNOS CEREBRALES

PID2019-105136RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease

  • Bortolozzi, Analía
  • Manashirov, Shanon
  • Chen, Alon
  • Artigas, Francesc
Remarkable advances in understanding the role of RNA in health and disease have expanded considerably in the last decade. RNA is becoming an increasingly important target for therapeutic intervention; therefore, it is critical to develop strategies for therapeutic modulation of RNA function. Oligonucleotides, including antisense oligonucleotide (ASO), small interfering RNA (siRNA), microRNA mimic (miRNA), and anti-microRNA (antagomir) are perhaps the most direct therapeutic strategies for addressing RNA. Among other mechanisms, most oligonucleotide designs involve the formation of a hybrid with RNA that promotes its degradation by activation of endogenous enzymes such as RNase-H (e.g., ASO) or the RISC complex (e.g. RNA interference - RNAi for siRNA and miRNA). However, the use of oligonucleotides for the treatment of brain disorders is seriously compromised by two main limitations: i) how to deliver oligonucleotides to the brain compartment, avoiding the action of peripheral RNAses? and once there, ii) how to target specific neuronal populations? We review the main molecular pathways in major depressive disorder (MDD) and Parkinson's disease (PD), and discuss the challenges associated with the development of novel oligonucleotide therapeutics. We pay special attention to the use of conjugated ligand-oligonucleotide approach in which the oligonucleotide sequence is covalently bound to monoamine transporter inhibitors (e.g. sertraline, reboxetine, indatraline). This strategy allows their selective accumulation in the monoamine neurons of mice and monkeys after their intranasal or intracerebroventricular administration, evoking preclinical changes predictive of a clinical therapeutic action after knocking-down disease-related genes. In addition, recent advances in oligonucleotide therapeutic clinical trials are also reviewed., This study was supported by grants SAF2016-75797-R and PID2019-105136RB-I00, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE (to A.B.); and CB/07/09/0034 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). We thank M. Calvo and E. Coll for outstanding technical support in the confocal microscopy unit (CCiT-UB). We also thank M. Jaramillo for helpful secretarial assistance. Fig. 1, Fig. 3 were generated using online application Motifolio Illustration Toolkits.com and Created with BioRender.com, respectively., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

mTOR knockdown in the infralimbic cortex evokes a depressive-like state in mouse

  • Garro-Martínez, Emilio
  • Fullana, Neus
  • Florensa-Zanuy, Eva
  • Senserrich, Júlia
  • Paz, Verónica
  • Ruiz-Bronchal, Esther
  • Adell, Albert
  • Castro, Elena
  • Díaz, Álvaro
  • Pazos, Ángel
  • Bortolozzi, Analía
  • Pilar-Cuéllar, Fuencisla
Fast and sustained antidepressant effects of ketamine identified the mammalian target of rapamycin (mTOR) signaling pathway as the main modulator of its antidepressive effects. Thus, mTOR signaling has become integral for the preclinical evaluation of novel compounds to treat depression. However, causality between mTOR and depression has yet to be determined. To address this, we knocked down mTOR expression in mice using an acute intracerebral infusion of small interfering RNAs (siRNA) in the infralimbic (IL) or prelimbic (PrL) cortices of the medial prefrontal cortex (mPFC), and evaluated depressive-and anxious-like behaviors. mTOR knockdown in IL, but not PrL, cortex produced a robust depressive-like phenotype in mice, as assessed in the forced swimming test (FST) and the tail suspension test (TST). This phenotype was associated with significant reductions of mTOR mRNA and protein levels 48 h post-infusion. In parallel, decreased brain-derived neurotrophic factor (BDNF) expression was found bilaterally in both IL and PrL cortices along with a dysregulation of serotonin (5-HT) and glutamate (Glu) release in the dorsal raphe nucleus (DRN). Overall, our results demonstrate causality between mTOR expression in the IL cortex and depressive-like behaviors, but not in anxiety., This research was funded by grants of the Ministerio de Economía y Competitividad (SAF2011-25020 and SAF2015-67457-R MINECO); Ministerio de Ciencia, Innovación y Universidades (RTI2018-097534-B-I00); Ministerio de Ciencia e Innovación (PID2019-105136RB-100); and the European Regional Development Fund (ERDF), UE; Instituto de Salud Carlos III (PI19/00170), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Human α-synuclein overexpression in mouse serotonin neurons elicits a depressive phenotype: Focus on brain connectivity and synaptic density

  • Torres-López, María
  • Miquel-Rio, Lluís
  • Paz, Verónica
  • Casal, Carme
  • Muñoz-Moreno, Emma
  • López-Gil, Xavier
  • Bortolozzi, Analía
Resumen del trabajo presentado en el 19th National Meeting of the Spanish Society of Neuroscience, celebrado en Lleida (España), del 3 al 5 de noviembre de 2021, Anxiety and depression are the most prevalent neuropsychiatric disorders in Parkinson’s disease (PD) population (50%), often preceding the appearance of motor symptoms. Neuropathological and neurochemical changes in the serotonin (5-HT) system occurs during PD prodromal phase and contributes to a variety of non-motor symptoms. However, anxiety/depression brain circuits in PD are not known in detail. In this study, we hypothesized that synaptic impairments occur in the early stages of the disease onset before the neuronal cell loss. Dysregulating the synaptic junction would block neurotransmitter release, thus triggering a retrograde neurodegenerative process ending with neuronal cell loss by proceeding through the axons. We aimed to study whether synaptic density and functional connections are affected by α-synuclein accumulation in efferent brain regions from 5-HT raphe nuclei in the early stages of a depression/PD-like mouse model. We overexpressed human wild-type or A53T mutant α-synuclein (WTα-Syn and A53Tα-Syn, respectively) in 5-HT neurons using AAV vectors and two different synaptic markers, microtubule-associated protein 2 (MAP-2) and synaptic vesicle glycoprotein 2A (SV2A) were examined 4 and 8 weeks later. Mice overexpressing WTα-Syn showed progressive reductions of MAP-2 levels in different 5-HT-inervated cortices (e.g. prelimbic, infralimbic, cingulate and motor cortices), caudate putamen and different sub-fields of hippocampus. In parallel, WTα-Syn mice showed also an accumulation of SV2A protein in cingulate and motor cortices, and caudate-putamen. In addition, changes of MAP-2 and SV2A synaptic markers were also found in different 5-HT projection brain areas of A53Tα-Syn mice, although these changes were of greater magnitude. Brain functional activity was examined in these mice using rsfRMI and early gene zif628 expression. Altogether, these data suggest that changes in the density of MAP-2 and SV2A synaptic markers linked to α-synuclein-induced axonal pathology lead to reduced 5-HT neurotransmission evoking a depressive-phenotype, and these effects precede neuronal degeneration., SAF2016-75797-R, PID2019-105136RB-100 (MINECO-ERDF), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice

  • Pavia-Collado, Rubén
  • Coppola-Segovia, Valentín
  • Miquel-Rio, Lluís
  • Alarcón-Arís, Diana
  • Rodríguez-Aller, Raquel
  • Torres-López, María
  • Paz, Verónica
  • Ruiz-Bronchal, Esther
  • Campa, Leticia
  • Artigas, Francesc
  • Montefeltro, Andrés
  • Revilla, Raquel
  • Bortolozzi, Analía
α-Synuclein (α-Syn) protein is involved in the pathogenesis of Parkinson’s disease (PD). Point mutations and multiplications of the α-Syn, which encodes the SNCA gene, are correlated with early-onset PD, therefore the reduction in a-Syn synthesis could be a potential therapy for PD if delivered to the key affected neurons. Several experimental strategies for PD have been developed in recent years using oligonucleotide therapeutics. However, some of them have failed or even caused neuronal toxicity. One limiting step in the success of oligonucleotide-based therapeutics is their delivery to the brain compartment, and once there, to selected neuronal populations. Previously, we developed an indatraline-conjugated antisense oligonucleotide (IND-1233-ASO), that selectively reduces α-Syn synthesis in midbrain monoamine neurons of mice, and nonhuman primates. Here, we extended these observations using a transgenic male mouse strain carrying both A30P and A53T mutant human α-Syn (A30P*A53T*α-Syn). We found that A30P*A53T*α-Syn mice at 4–5 months of age showed 3.5-fold increases in human α-Syn expression in dopamine (DA) and norepinephrine (NE) neurons of the substantia nigra pars compacta (SNc) and locus coeruleus (LC), respectively, compared with mouse α-Syn levels. In parallel, transgenic mice exhibited altered nigrostriatal DA neurotransmission, motor alterations, and an anxiety-like phenotype. Intracerebroventricular IND-1233-ASO administration (100 µg/day, 28 days) prevented the α-Syn synthesis and accumulation in the SNc and LC, and recovered DA neurotransmission, although it did not reverse the behavioral phenotype. Therefore, the present therapeutic strategy based on a conjugated ASO could be used for the selective inhibition of α-Syn expression in PD-vulnerable monoamine neurons, showing the benefit of the optimization of ASO molecules as a disease modifying therapy for PD and related α-synucleinopathies., This study was supported by grants SAF2016-75797-R, PID2019-105136RB-100, Retos- Colaboración Subprogram RTC-2015-3309-1, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Food craving-like episodes during pregnancy are mediated by accumbal dopaminergic circuits

  • Haddad-Tóvolli, Roberta
  • Ramírez, Sara
  • Muñoz-Moreno, Emma
  • Milà, Montserrat
  • Miquel-Rio, Lluís
  • Pozo, Macarena
  • Chivite, Iñigo
  • Altirriba, Jordi
  • Obri, Arnaud
  • Gómez-Valadés, Alicia
  • Toledo, Miriam
  • Eyre, Elena
  • Bortolozzi, Analía
  • Valjent, Emmanuel
  • Soria, Guadalupe
  • Claret, Marc
Preparation for motherhood requires a myriad of physiological and behavioural adjustments throughout gestation to provide an adequate environment for proper embryonic development. Cravings for highly palatable foods are highly prevalent during pregnancy and contribute to the maintenance and development of gestational overweight or obesity. However, the neurobiology underlying the distinct ingestive behaviours that result from craving specific foods remain unknown. Here we show that mice, similarly to humans, experience gestational food craving-like episodes. These episodes are associated with a brain connectivity reorganization that affects key components of the dopaminergic mesolimbic circuitry, which drives motivated appetitive behaviours and facilitates the perception of rewarding stimuli. Pregnancy engages a dynamic modulation of dopaminergic signalling through neurons expressing dopamine D2 receptors in the nucleus accumbens, which directly modulate food craving-like events. Importantly, persistent maternal food craving-like behaviour has long-lasting effects on the offspring, particularly in males, leading to glucose intolerance, increased body weight and increased susceptibility to develop eating disorders and anxiety-like behaviours during adulthood. Our results reveal the cognitively motivated nature of pregnancy food cravings and advocates for moderating emotional eating during gestation to prevent deterioration of the offspring’s neuropsychological and metabolic health., This study was funded by the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 725004) and supported by: ‘la Caixa’ Foundation (ID100010434) under agreement LCF/PR/HR19/52160016 and the CERCA Programme/Generalitat de Catalunya (to M.C.); grant no. PID2019-105136RB-100, Spanish Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF; to A.B.); Marie Skłodowska-Curie Action fellowship (H2020-MSCA-IF) NEUROPREG (grant agreement no. 891247; to R.H-T.); the Spanish Ministry of Science and Innovation, Juan de la Cierva fellowship (IJC2018-037341-I to S.R.); Miguel Servet contract (CP19/00083) from Instituto de Salud Carlos III co-financed by ERDF (to A.O.). This work was carried out in part at the Esther Koplowitz Centre.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy

  • Miquel-Rio, Lluís
  • Alarcón-Arís, Diana
  • Torres-López, María
  • Coppola-Segovia, Valentín
  • Pavia-Collado, Rubén
  • Paz, Verónica
  • Ruiz-Bronchal, Esther
  • Campa, Leticia
  • Casal, Carme
  • Montefeltro, Andrés
  • Vila, Miquel
  • Artigas, Francesc
  • Revilla, Raquel
  • Bortolozzi, Analía
Anxiety and depression affect 35–50% of patients with Parkinson’s disease (PD), often precede the onset of motor symptoms, and have a negative impact on their quality of life. Dysfunction of the serotonergic (5-HT) system, which regulates mood and emotional pathways, occurs during the premotor phase of PD and contributes to a variety of non-motor symptoms. Furthermore, α-synuclein (α-Syn) aggregates were identified in raphe nuclei in the early stages of the disease. However, there are very few animal models of PD-related neuropsychiatric disorders. Here, we develop a new mouse model of α-synucleinopathy in the 5-HT system that mimics prominent histopathological and neuropsychiatric features of human PD. We showed that adeno-associated virus (AAV5)-induced overexpression of wild-type human α-Syn (h-α-Syn) in raphe 5-HT neurons triggers progressive accumulation, phosphorylation, and aggregation of h-α-Syn protein in the 5-HT system. Specifically, AAV5-injected mice displayed axonal impairment in the output brain regions of raphe neurons, and deficits in brain-derived neurotrophic factor (BDNF) expression and 5-HT neurotransmission, resulting in a depressive-like phenotype. Intracerebroventricular treatment with an indatraline-conjugated antisense oligonucleotide (IND-ASO) for four weeks induced an effective and safe reduction of h-α-Syn synthesis in 5-HT neurons and its accumulation in the forebrain, alleviating early deficits of 5-HT function and improving the behavioural phenotype. Altogether, our findings show that α-synucleinopathy in 5-HT neurons negatively affects brain circuits that control mood and emotions, resembling the expression of neuropsychiatric symptoms occurring at the onset of PD. Early preservation of 5-HT function by reducing α-Syn synthesis/accumulation may alleviate PD-related depressive symptoms., We thank to the Coordenação de Aperfeiçoamento de Nivel Superior (CAPES-PDSE: 19/2016 88881.135527/2016-01), Brazil, for their financial support via a scholarship awarded to C.C.-S. We also thank JAE-Intro Program, CSIC (JAEINT_20_02116), Spain, for their financial support via a scholarship awarded to M.T.-L. This study was supported by grants SAF2016-75797-R, PID2019-105136RB-100, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson’s Disease

  • Dupont, Annabelle
  • Bortolozzi, Analía
  • Sgambato, Véronique
Parkinson’s disease (PD) is characterized by cell loss in the substantia nigra and the presence of alpha-synuclein (α-syn)-containing neuronal Lewy bodies. While α-syn has received major interest in the pathogenesis of PD, the function of beta- and gamma-synucleins (β-syn and γ-syn, respectively) is not really known. Yet, these proteins are members of the same family and also concentrated in neuronal terminals. The current preclinical study investigated the expression levels of α-, β-, and γ-synucleins in brainstem regions involved in PD physiopathology. We analyzed synuclein expression in the substantia nigra, raphe nuclei, pedunculopontine nucleus, and locus coeruleus from control and parkinsonian (by MPTP) macaques. MPTP-intoxicated monkeys developed a more or less severe parkinsonian score and were sacrificed after a variable post-MPTP period ranging from 1 to 20 months. The expression of the three synucleins was increased in the substantia nigra after MPTP, and this increase correlates positively, although not very strongly, with cell loss and motor score and not with the time elapsed after intoxication. In the dorsal raphe nucleus, the expression of the three synucleins was also increased, but only α- and γ-Syn are linked to the motor score and associated cell loss. Finally, although no change in synuclein expression was demonstrated in the locus coeruleus after MPTP, we found increased expression levels of γ-Syn, which are only correlated with cell loss in the pedunculopontine nucleus. Altogether, our data suggest that these proteins may play a key role in brainstem regions and mesencephalic tegmentum. Given the involvement of these brain regions in non-motor symptoms of PD, these data also strengthen the relevance of the MPTP macaque model of PD, which exhibits pathological changes beyond nigral DA cell loss and α-synucleinopathy., This research was funded by Fondation de France, Agence Nationale de la Recherche, Grant PID2019-105136RB-100; Ministry of Science and Innovation (MICINN); and European Regional Development Fund (ERDF), EU.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson's disease

  • Pavia-Collado, Rubén
  • Miquel-Rio, Lluís
  • Campa, Leticia
  • Bortolozzi, Analía
Here, we present an optimized protocol for generating a mouse model overexpressing human α-synuclein in dopamine (DA) neurons driven by an adeno-associated viral (AAV) vector and for the examination of the benefit of an antisense oligonucleotide (ASO)-based therapy on DA neurotransmission under Parkinson's disease (PD)-like conditions. We describe AAV injection, followed by implantation of an osmotic minipump for ASO delivery and a guide cannula for microdialysis to measure DA release. This protocol can be used to evaluate oligonucleotide-based therapies for PD. For complete details on the use and execution of this protocol, please refer to Alarcón-Arís et al. (2020)., This study was supported by grants SAF2016-75797-R and PID2019-105136RB-100, Ministry of Science and Innovation (MICINN) and European Regional Development Fund (ERDF), EU, and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Up and Down γ‐Synuclein Transcription in Dopamine Neurons Translates into Changes in Dopamine Neurotransmission and Behavioral Performance in Mice

  • Pavia-Collado, Rubén
  • Rodríguez-Aller, Raquel
  • Alarcón-Arís, Diana
  • Miquel-Rio, Lluís
  • Ruiz-Bronchal, Esther
  • Paz, Verónica
  • Campa, Leticia
  • Galofré, Mireia
  • Sgambato, Véronique
  • Bortolozzi, Analía
The synuclein family consists of α‐, β‐, and γ‐Synuclein (α‐Syn, β‐Syn, and γ‐Syn) expressed in the neurons and concentrated in synaptic terminals. While α‐Syn is at the center of interest due to its implication in the pathogenesis of Parkinson’s disease (PD) and other synucleinopathies, limited information exists on the other members. The current study aimed at investigating the biological role of γ‐Syn controlling the midbrain dopamine (DA) function. We generated two different mouse models with: (i) γ‐Syn overexpression induced by an adeno‐associated viral vector and (ii) γ‐Syn knockdown induced by a ligand‐conjugated antisense oligonucleotide, in order to modify the endogenous γ‐Syn transcription levels in midbrain DA neurons. The progressive overexpression of γ‐Syn decreased DA neurotransmission in the nigrostriatal and mesocortical pathways. In parallel, mice evoked motor deficits in the rotarod and impaired cognitive performance as assessed by novel object recognition, passive avoidance, and Morris water maze tests. Conversely, acute γ‐Syn knockdown selectively in DA neurons facilitated forebrain DA neurotransmission. Importantly, modifications in γ‐Syn expression did not induce the loss of DA neurons or changes in α‐Syn expression. Collectively, our data strongly suggest that DA release/re‐uptake processes in the nigrostriatal and mesocortical pathways are partially dependent on substantia nigra pars compacta /ventral tegmental area (SNc/VTA) γ‐Syn transcription levels, and are linked to modulation of DA transporter function, similar to α‐Syn., This research was funded by grants SAF2016-75797-R, PID2019-105136RB-100, Ministry of Science and Innovation (MICINN) and European Regional Development Fund (ERDF), EU; and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages

  • Calero, Macarena
  • Moleiro, Lara H.
  • Sayd, Aline
  • Dorca, Yeray
  • Miquel-Rio, Lluís
  • Paz, Verónica
  • Robledo-Montaña, Javier
  • Enciso, Eduardo
  • Acción, Fernando
  • Herráez-Aguilar, Diego
  • Hellweg, Thomas
  • Sánchez, Luis
  • Bortolozzi, Analía
  • Leza, Juan C.
  • García-Bueno, Borja
  • Monroy, Francisco
A colloidal synthesis’ proof-of-concept based on the Bligh–Dyer emulsion inversion method was designed for integrating into lipid nanoparticles (LNPs) cell-permeating DNA antisense oligonucleotides (ASOs), also known as GapmeRs (GRs), for mRNA interference. The GR@LNPs were formulated to target brain border-associated macrophages (BAMs) as a central nervous system (CNS) therapy platform for silencing neuroinflammation-related genes. We specifically aim at inhibiting the expression of the gene encoding for lipocalin-type prostaglandin D synthase (L-PGDS), an anti-inflammatory enzyme expressed in BAMs, whose level of expression is altered in neuropsychopathologies such as depression and schizophrenia. The GR@LNPs are expected to demonstrate a bio-orthogonal genetic activity reacting with L-PGDS gene transcripts inside the living system without interfering with other genetic or biochemical circuitries. To facilitate selective BAM phagocytosis and avoid subsidiary absorption by other cells, they were functionalized with a mannosylated lipid as a specific MAN ligand for the mannose receptor presented by the macrophage surface. The GR@LNPs showed a high GR-packing density in a compact multilamellar configuration as structurally characterized by light scattering, zeta potential, and transmission electronic microscopy. As a preliminary biological evaluation of the mannosylated GR@LNP nanovectors into specifically targeted BAMs, we detected in vivo gene interference after brain delivery by intracerebroventricular injection (ICV) in Wistar rats subjected to gene therapy protocol. The results pave the way towards novel gene therapy platforms for advanced treatment of neuroinflammation-related pathologies with ASO@LNP nanovectors., This study was funded by the REACT-EU program PR38-21-28 ANTICIPA-CM, a grant by Comunidad de Madrid and European Union under FEDER program, from European Union in response to COVID-19 pandemics. The funders had no role in the study design, data collection, analysis, preparation of the manuscript, or the decision to publish. The work was also supported by the Spanish Ministry of Science and Innovation (MICINN–Agencia Española de Investigación AEI) under grants PID 2019-108391RB-100 (to FM) and PID 2019-105136RB-100 (to AB), the Ministry of Economy, Industry, and Competitiveness under grant SAF 2012-38123 (to BG-B), Comunidad de Madrid under grants S2018/NMT-4389 and Y2018/BIO-5207 (to FM), and European Regional Development Fund (ERDF), European Union (to AB), and CIBERSAM (to JL). The invented procedure is protected under the Spanish patent ES201800272.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ketamine triggers rapid antidepressant effects by modulating synaptic plasticity in a new depressive-like mouse model based on astrocyte glutamate transporter GLT-1 knockdown in infralimbic cortex, La ketamina desencadena efectos antidepresivos rápidos en un nuevo modelo de ratón con fenotipo depresivo basado en la reducción del transportador de glutamato de astrocitos GLT-1 en la corteza infralímbica mediante la modulación de la plasticidad sináptica

  • Fullana, Neus
  • Paz, Verónica
  • Artigas, Francesc
  • Bortolozzi, Analía
[EN] Objective Recently, we reported on a new MDD-like mouse model based on a regionally selective knockdown of astroglial glutamate transporters, GLAST/GLT-1, in infralimbic cortex (IL) which evokes widespread changes in mouse brain associated with the typical alterations found in MDD patients. To further characterize this new MDD-like mouse model, here we examine some transcriptional elements of glutamatergic/GABAergic neurotransmission and neuroplasticity in forebrain regions in the GLT-1 knockdown mice. Furthermore, we assess the acute ketamine effects on these transcriptional processes. Material and methods We used a small interfering RNA (siRNA) pool targeting GLT-1 mRNA to disrupt the GLT-1 transcription in mouse IL. Histological assays were performed to examine postsynaptic density protein-95 (PSD95), neuritin (NRN), glutamine acid descarboxilase-65 (GAD65), and GLT-1 mRNA expression in IL and hippocampus. Results Knockdown of GLT-1 in mouse IL leads to decreased expression of PSD95 and NRN neuroplasticity mRNAs in IL and hippocampus, which was reversed by an acute dose of ketamine antidepressant. Likewise, a single dose of ketamine also increased the mRNA levels of GAD65 and GLT-1 in IL of GLT-1 knockdown mice, reaching the basal values of control mice. Conclusions The glutamatergic neuronal hyperactivity and deficits in the GABA system resulting from siRNA-induced astroglial glutamate transporter knockdown in IL can compromise the integrity/plasticity of neurocircuits affected in MDD. Suitable depressive-like animal models to address the neurobiological changes in MDD are an unmet need and the development of the GLAST/GLT-1 knockdown mouse model may represent a better option to understand the rapid-acting antidepressant effects of ketamine., [ES] Objetivo Recientemente, informamos sobre un nuevo modelo de ratón de depresión basado en una reducción parcial de la transcripción de los transportadores de glutamato, GLAST/GLT-1, en los astrocitos de la corteza infralímbica (IL), que conduce a cambios generalizados de la función cerebral del ratón, que refleja alteraciones típicas encontradas en pacientes con depresión. Para caracterizar más detalladamente este nuevo modelo de ratón de depresión, aquí examinamos algunos elementos transcripcionales relacionados con la neurotransmisión glutamatérgica/GABAérgica y la neuroplasticidad en regiones corticales y subcorticales de los ratones con niveles reducidos de GLT-1. Además, evaluamos los efectos agudos de la ketamina, antidepresivo de acción rápida, en estos procesos transcripcionales. Material y métodos Utilizamos ARN de interferencia (siRNA) dirigido al mRNA de GLT-1 para interrumpir su transcripción en la IL de ratón. Se realizaron ensayos histológicos para examinar la expresión de los mRNA de las siguientes proteínas: proteína de densidad postsináptica-95 (PSD95), neuritina (NRN), descarboxilasa de ácido glutámico-65 (GAD65) y GLT-1 en la IL e hipocampo. Resultados La reducción de la expresión de GLT-1 en IL de ratón conduce a una disminución de la expresión de los mRNA de neuroplasticidad PSD95 y NRN en la IL y el hipocampo, efecto que se revirtió con una única administración del antidepresivo ketamina. Asimismo, una sola dosis de ketamina también aumentó los niveles de los mRNA de GAD65 y GLT-1 en la IL de ratones silenciados para GLT-1, que alcanzaron los valores basales de los ratones control. Conclusiones La hiperactividad neuronal glutamatérgica y los déficits en el sistema GABAérgico resultantes de la reducción de los niveles del transportador de glutamato astroglial inducida por siRNA en IL pueden comprometer la integridad/plasticidad de aquellos neurocircuitos afectados en la depresión. Sin embargo, no disponemos de modelos animales de depresión adecuados para abordar los cambios neurobiológicos que se suceden en esta enfermedad y su tratamiento. El desarrollo del modelo de ratón con reducción parcial de GLAST/GLT-1 puede representar una mejor opción para comprender los efectos antidepresivos de acción rápida de la ketamina., This study was supported by grants SAF2016-75797-R, PID2019-105136RB-100, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

  • Tristán-Noguero, Alba
  • Fernández-Carasa, Irene
  • Calatayud, Carles
  • Bermejo-Casadesús, Cristina
  • Pons-Espinal, Meritxell
  • Colini Baldeschi, Arianna
  • Campa, Leticia
  • Artigas, Francesc
  • Bortolozzi, Analía
  • Domingo-Jiménez, Rosario
  • Ibáñez, Salvador
  • Pineda, Mercè
  • Artuch, Rafael
  • Raya, Ángel
  • García-Cazorla, Àngels
  • Consiglio, Antonella
Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management., The authors are indebted to the THD patients who have participated in this study. The authors thank Bernd Kuebler and Begoña Aran from the P-CMR[C] Stem Cell Bank, for generating the THD iPSCs. We would like to thank Marcia Triunfol and João Mello-Vieira at Publicase for their help with this manuscript. Research from the authors' laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL) and ERC 2020-PoC (957581 NeurAntigen), the Spanish Ministry of Economy and Competitiveness-MINECO (PID2019-108792GB-I00, PID2019-105136RB-100, PID2021-123925OB-I00, PDC2021-121051-I00 and RTI2018-095377-B-100), supported by MCIN/AEI/10.13039/501100011033 and “NextGenerationEU/PRTR”, Instituto de Salud Carlos III-ISCIII/ and “Fondo Europeo de desarrollo regional” (FEDER) (Red de Terapia Celular - TerCel RD16/0011/0024, FIS PI15/01082, P118/00111), Agencia Estatal de Investigación-AEI (Unidad de Excelencia María de Maeztu CEX2018-000792-M), AGAUR (2017-SGR-899 and 2017-SGR-1061), Fundació la Marató de TV3 (202012-31 and 202012-32) and CERCA Programme/Generalitat de Catalunya. CC was partially supported by predoctoral fellowship (FPU12/03332) from the Spanish Ministry of Education (MEC). AT-N was partially supported by a PFIS pre-doctoral fellowship (FI14/00641) from the Instituto de Salud Carlos III-ISCIII and 2018BR-IRSJD-CdTorres from Sant Joan de Déu Hospital. AC is a recipient of an ICREA “Academia” Award (Generalitat de Catalunya)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Role of α-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features

  • Miquel-Rio, Lluís
  • Sarries-Serrano, Unai
  • Pavia-Collado, Rubén
  • Meana, J. Javier
  • Bortolozzi, Analía
In patients affected by Parkinson’s disease (PD), up to 50% of them experience cognitive changes, and psychiatric disturbances, such as anxiety and depression, often precede the onset of motor symptoms and have a negative impact on their quality of life. Pathologically, PD is characterized by the loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNc) and the presence of intracellular inclusions, called Lewy bodies and Lewy neurites, composed mostly of α-synuclein (α-Syn). Much of PD research has focused on the role of α-Syn aggregates in the degeneration of SNc DA neurons due to the impact of striatal DA deficits on classical motor phenotypes. However, abundant Lewy pathology is also found in other brain regions including the midbrain raphe nuclei, which may contribute to non-motor symptoms. Indeed, dysfunction of the serotonergic (5-HT) system, which regulates mood and emotional pathways, occurs during the premotor phase of PD. However, little is known about the functional consequences of α-Syn inclusions in this neuronal population other than DA neurons. Here, we provide an overview of the current knowledge of α-Syn and its role in regulating the 5-HT function in health and disease. Understanding the relative contributions to α-Syn-linked alterations in the 5-HT system may provide a basis for identifying PD patients at risk for developing depression and could lead to a more targeted therapeutic approach., This research was funded by grants PID2019-105136RB-100, MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe, by the Euro-pean Union, and CB/07/09/0034 and CB/07/09/0008 Center for Networked Biomedical Research on Mental Health (CIBERSAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Thalamic Foxp2 regulates output connectivity and sensory-motor impairments in a model of Huntington's Disease

  • Rodríguez-Urgellés, Ened
  • Casas-Torremocha, Diana
  • Sancho-Balsells, Anna
  • Ballasch, Iván
  • García-García, Esther
  • Miquel-Rio, Lluís
  • Manasanch, Arnau
  • Del Castillo, Ignacio
  • Chen, Wanqi
  • Pupak, Anika
  • Brito, Veronica
  • Tornero, Daniel
  • Rodríguez, Manuel J.
  • Bortolozzi, Analía
  • Sanchez-Vives, Maria V.
  • Giralt, Albert
  • Alberch, Jordi
Huntington's Disease (HD) is a disorder that affects body movements. Altered glutamatergic innervation of the striatum is a major hallmark of the disease. Approximately 30% of those glutamatergic inputs come from thalamic nuclei. Foxp2 is a transcription factor involved in cell differentiation and reported low in patients with HD. However, the role of the Foxp2 in the thalamus in HD remains unexplored., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. AG is a Ramón y Cajal fellow (RYC-2016–19466). This work was supported by grants from Ministerio de Ciencia e Innovación/ AEI/10.13039/501100011033/ and “FEDER”: AG: PID2021-122258OB-I00; MVSV: PID2020-112947RB-I00; AB: PID2019-105136RB-100; DT: PID2020-118120RB-I00; JA & MJR: PID2020-119386RB-100. Funded by H2020 Grant Agreement No. 945539 (Human Brain Project SGA3 to MVSV). IDIBAPS is funded by the CERCA program (Generalitat de Catalunya)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Enfermedad de Parkinson, depresión y su comorbilidad. Rol del estrés del retículo endoplasmático en el sistema serotoninérgico

  • Miquel-Rio, Lluís
Trabajo presentado para lograr el título de Doctor por la Universidad de Barcelona, Programa de Doctorado en Biomedicina, El retículo endoplásmico (RE) desempeña un papel clave en el control de la calidad y plegamiento adecuado de las proteínas. En condiciones fisiológicas, la homeostasis del ER es un proceso estrictamente regulado. La acumulación de proteínas plegadas incorrectamente activa las vías de señalización UPR (unfolded protein response), que implica tres sensores de estrés del ER para restaurar el equilibrio del mismo. Sin embargo, bajo estrés crónico del ER, UPR se desregula y desencadena una defectuosa proteostasis que conduce a la disfunción celular y muerte. Dado que la acumulación de alfa-sinucleína mal plegada es un proceso patógeno fundamental en la enfermedad de Parkinson (PD), no es sorprendente que los marcadores de la vía de ER estén alterados en los cerebros de pacientes con PD. Las proteínas ER asociadas al estrés como BIP, PERK o eIF2a están aumentadas en la sustancia nigra de los pacientes con PD y algunas se localizan conjuntamente con cuerpos de Lewy. Por lo tanto, el estrés del ER está involucrado en la patogénesis de PD; sin embargo, no está claro si la acumulación de alfa-sinucleína agregada es la causa o ela consecuencia del estrés ER/UPR alterada. Usando modelos de ratón de 1) sobre-expresión de alfa-sinucleína humana wild-type o con la mutacion A53T inducida por AAV5, 2) estrés de ER inducido por tunicamicina y 3) combinación de ellos, dilucidaremos si existe una relación causal entre el estrés de ER y la agregación de alfa-sinucleína en las neuronas monoaminérgicas del mesencáfalo (neuronas dopaminergicas, serotonergicas y noradrenergicas) que típicamente exhiben patología de alfa-sinucleína. Además, evaluaremos nuevas estrategias terapéuticas, incluyendo 1) agentes farmacológicos (proteínas chaperones aprobados por la FDA) y 2) terapia génica incluyendo oligonucleótidos inhibitorios no-virales contra componentes del estrés del ER dirigidos de una manera selectiva hacia las neuronas monoaminérgicas. Para abordar el proyecto se incluirán varias aproximaciones tales como procedimientos moleculares, celulares, electrofisiológicos y de fenotipado conductual., El presente trabajo ha sido financiado por los siguientes proyectos: - “Sinucleinopatías y oligonucleótidos inhibitorios: Rol de α- y γ-sinucleínas en la regulación de la función cognitiva” con código SAF2016-75797-R, financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). - “Linking between endoplasmic reticulum stress and alpha-synucleinopathy in brain disorders (ERASBRADI)” con código PID2019-105136RB-I00, financiado por el Ministerio de Ciencia e Innovación (MINECO). - “Depression and its treatment: Role of miRNAs in the anterior cingulate cortex, as peripheral biomarkers, and their targeted modulation by nano-tools as a promising antidepressant therapy”. Proyecto financiado por Fundació la Marató TV3. - Grupo CB/07/09/0034, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III. - Grup de Recerca Consolidat, Trastorns Bipolars i Depressius. Referencia: AGAUR 2021-SGR01358. Financiación de la Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ER stress in mouse serotonin neurons triggers a depressive phenotype alleviated by ketamine targeting eIF2α signaling

  • Miquel-Rio, Lluís
  • Sarries-Serrano, Unai
  • Sancho-Alonso, María
  • Florensa-Zanuy, Eva
  • Paz, Verónica
  • Ruiz-Bronchal, Esther
  • Manashirov, Shanon
  • Campa, Leticia
  • Pilar-Cuéllar, Fuencisla
  • Bortolozzi, Analía
Depression is a devastating mood disorder that causes significant disability worldwide. Current knowledge of its pathophysiology remains modest and clear biological markers are lacking. Emerging evidence from human and animal models reveals persistent alterations in endoplasmic reticulum (ER) homeostasis, suggesting that ER stress-related signaling pathways may be targets for prevention and treatment. However, the neurobiological basis linking the pathways involved in depression-related ER stress remains unknown. Here, we report that an induced model of ER stress in mouse serotonin (5-HT) neurons is associated with reduced Egr1-dependent 5-HT cellular activity and 5-HT neurotransmission, resulting in neuroplasticity deficits in forebrain regions and a depressive-like phenotype. Ketamine administration engages downstream eIF2α signaling to trigger rapid neuroplasticity events that rescue the depressive-like effects. Collectively, these data identify ER stress in 5-HT neurons as a cellular pathway involved in the pathophysiology of depression and show that eIF2α is critical in eliciting ketamine's fast antidepressant effects., This work was supported by MCIU/AEI/FEDER, UE grant ( PID2019-105136RB-100 , MCIN/AEI/10.13039/501100011033 to AB, and SAF2015-67457-R to FPC), Fundación La Marató TV3 ( 202207 ), and AGAUR 2021-SGR-01358 , Catalan Government. CB/07/09/0034 and CB/07/09/0008 Center for Networked Biomedical Research on Mental Health (CIBERSAM). We also thank the Spanish Stress Research Network, MCIN/AEI/10.13039/501100011033. USS is a recipient of a fellowship from the Non-Doctor Researcher Formation Pre-doctoral Program of Basque Government, Spain. MSA has a Margarita Salas Grant ( MS21-132 ) from the University of Valencia (requalification of the Spanish University System of the Ministry of Universities of the Government of Spain, financed by the European Union, Next Generation EU)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview

  • Bortolozzi, Analía
  • Fico, Giovanna
  • Berk, Michael
  • Solmi, Marco
  • Fornaro, Michele
  • Quevedo, Joao
  • Zarate, Carlos A.
  • Kessing, Lars V.
  • Vieta, Eduard
  • Carvalho, Andre F.
Over the last six decades, lithium has been considered the gold standard treatment for the long-term management of bipolar disorder due to its efficacy in preventing both manic and depressive episodes as well as suicidal behaviors. Nevertheless, despite numerous observed effects on various cellular pathways and biologic systems, the precise mechanism through which lithium stabilizes mood remains elusive. Furthermore, there is recent support for the therapeutic potential of lithium in other brain diseases. This review offers a comprehensive examination of contemporary understanding and predominant theories concerning the diverse mechanisms underlying lithium's effects. These findings are based on investigations utilizing cellular and animal models of neurodegenerative and psychiatric disorders. Recent studies have provided additional support for the significance of glycogen synthase kinase-3 (GSK3) inhibition as a crucial mechanism. Furthermore, research has shed more light on the interconnections between GSK3-mediated neuroprotective, antioxidant, and neuroplasticity processes. Moreover, recent advancements in animal and human models have provided valuable insights into how lithium-induced modifications at the homeostatic synaptic plasticity level may play a pivotal role in its clinical effectiveness. We focused on findings from translational studies suggesting that lithium may interface with microRNA expression. Finally, we are exploring the repurposing potential of lithium beyond bipolar disorder. These recent findings on the therapeutic mechanisms of lithium have provided important clues toward developing predictive models of response to lithium treatment and identifying new biologic targets. SIGNIFICANCE STATEMENT: Lithium is the drug of choice for the treatment of bipolar disorder, but its mechanism of action in stabilizing mood remains elusive. This review presents the latest evidence on lithium's various mechanisms of action. Recent evidence has strengthened glycogen synthase kinase-3 (GSK3) inhibition, changes at the level of homeostatic synaptic plasticity, and regulation of microRNA expression as key mechanisms, providing an intriguing perspective that may help bridge the mechanistic gap between molecular functions and its clinical efficacy as a mood stabilizer., This work was supported by Grant PID2019-105136RB-100 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (to A.B.). M.B. is supported by a NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator Grant (1156072 and 2017131). G.F.'s work is supported by a fellowship from “La Caixa” Foundation (ID 100010434 - fellowship code LCF/BQ/DR21/11880019)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Scn1a haploinsufficiency in the prefrontal cortex leads to cognitive impairment and depressive phenotype

  • Riga, Maurizio S.
  • Pérez-Fernández, Mercedes
  • Miquel-Rio, Lluís
  • Paz, Verónica
  • Campa, Leticia
  • Martínez-Losa, Magdalena
  • Esteban, Francisco J.
  • Callado, Luis F.
  • Meana, Javier
  • Artigas, Francesc
  • Bortolozzi, Analía
  • Álvarez-Dolado, Manuel
Altered development and function of the prefrontal cortex (PFC) during adolescence is implicated in the origin of mental disorders. Deficits in the GABAergic system prominently contribute to these alterations. Nav1.1 is a voltage-gated Na+ channel critical for normal GABAergic activity. Here, we studied the role of Nav1.1 in PFC function and its potential relationship with the aetiology of mental disorders. Dysfunction of Nav1.1 activity in the medial PFC (mPFC) of adolescent mice enhanced the local excitation/inhibition ratio, resulting in epileptic activity, cognitive deficits and depressive-like behaviour in adulthood, along with a gene expression profile linked to major depressive disorder (MDD). Additionally, it reduced extracellular serotonin concentration in the dorsal raphe nucleus and brain-derived neurotrophic factor expression in the hippocampus, two MDD-related brain areas beyond the PFC. We also observed alterations in oscillatory activity and impaired hippocampal-mPFC coherence during sleep. Finally, we found reduced expression levels of SCN1A, the gene encoding Nav1.1, in post-mortem PFC samples from human MDD subjects. Collectively, our results provide a novel mechanistic framework linking adolescence-specific alterations in Nav1.1 function in the PFC to the pathogenesis of epilepsy and comorbidities such as cognitive impairment and depressive disorders., This work was supported by the Ministerio de Ciencia Innovación y Universidades/Agencia Estatal de Investigación/European Regional Development Fund, UE Grants (RTI2018-099768-B-100; PID2021-127044OB-I00 to M.A.-D.; PID2019-105136RB-100 to A.B.; and PID2021-122991NB-C21 to F.J.E.), Asociación Apoyo Dravet to M.A.-D., Fundació La Marató de TV3 and Generalitat de Catalunya (202207) to A.B., Center for Networked Biomedical Research on Mental Health, CIBERSAM (CB/07/09/0034 and CB/07/09/0008) to A.B. and J.M., European Regional Development Fund for Andalucía 2014-2020 (US-1264375) to M.M.-L., Universidad de Jaén (PAIUJA-EI_CTS02_2023)—Junta de Andalucía (BIO-302) to F.J.E., Fundación Alicia Koplowitz (OTR08262-2021) and Asociación Síndrome STXBP1 to M.A.-D. and F.J.E., Basque Government (IT211/19 and IT1512/22) to J.M. and L.F.C., and a Consejería de Salud y Familias, Junta de Andalucía, postdoctoral fellowship (RH-0048-2020) to M.S.R., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired unfolded protein response, BDNF and synuclein markers in postmortem dorsolateral prefrontal cortex and caudate nucleus of patients with depression and Parkinson's disease

  • Sarries-Serrano, Unai
  • Miquel-Rio, Lluís
  • Santana, Noemí
  • Paz, Verónica
  • Sancho-Alonso, María
  • Callado, Luis F.
  • Meana, J. Javier
  • Bortolozzi, Analía
Major depressive disorder (MDD) is characterized by significant impairment in social, emotional, and cognitive functioning. Its precise pathophysiology remains poorly understood. Alterations in protein homeostasis and some misfolded proteins have been identified within the brains of patients diagnosed with neuropsychiatric disorders. In contrast to neurodegenerative processes such as Parkinson's disease (PD), where the accumulation of aggregated α-synuclein (α-Syn) protein is a primary cause of significant neuronal loss, altered proteostasis in MDD may result in loss-of-function effects by modifying synaptic neuroplasticity. Moreover, aberrant activation of endoplasmic reticulum (ER) pathways may intensify the pathological alterations due to altered proteostasis. In this study, dorsolateral prefrontal cortex (dlPFC) and caudate nucleus from MDD patients and non-psychiatric controls were used. Postmortem samples of same brain areas from PD patients (Braak 2-3 and 5-6) and controls were also included. Protein levels of ER and unfolded protein response (UPR), synucleins (α-, β- and γ-Syn), and brain-derived neurotrophic factor (BDNF) were measured by Western-Blot. Phospho-eIF2α/eIF2α ratio was increased in the dlPFC and caudate nucleus of MDD and PD patients compared to their respective controls. Brain area-dependent changes in BiP and GRP94 levels were also found. We further detected accumulation of immature BDNF precursors and opposite changes in α- and β-Syn levels in the dlPFC of MDD and PD patients compared to controls. Our findings suggest that alterations in proteostasis contribute to the pathophysiology of MDD, as previously described in PD. A deeper understanding of the pathways involved will identify other candidate proteins and new targets with therapeutic potential., This work has been funded by MCIU/AEI/FEDER, an EU grant (PID2019-105136RB-100, PID2022-141700OB-I00, MCIN/AEI/10. 13039/501100011033 to AB), and AGAUR 2021-SGR-01358, Government of Catalonia, Basque Government (IT1512/22), CB/07/09/0034 and CB/07/09/0008 Centre for Biomedical Research in Mental Health Network (CIBERSAM). We would also like to thank the Spanish Network for Research on Stress, MCIN/AEI/10.13039/501100011033. USS has received a grant from the Training Programme for Non-Doctoral Pre-doctoral Researchers of the Basque Government, Spain. MSA has a Margarita Salas Scholarship (MS21-132) from the University of Valencia (reclassification of the Spanish University System of the Ministry of Universities of the Government of Spain, financed by the European Union, Next Generation EU). The authors would like to thank the staff members of the Basque Institute of Legal Medicine for their collaboration in the study., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Early synaptic changes and reduced brain connectivity in PD-like mice with depressive phenotype

  • Miquel-Rio, Lluís
  • Jericó-Escolar, Judith
  • Sarries-Serrano, Unai
  • Yanes-Castilla, Claudia
  • Torres-López, María
  • Argibay, Uxia
  • Paz, Verónica
  • Casal, Carme
  • Muñoz-Moreno, Emma
  • López-Gil, Xavier
  • Bortolozzi, Analía
Anxiety and depression are common in Parkinson’s disease (PD), affecting quality of life. Aggregates of α-synuclein (α-Syn) are found in serotonergic (5-HT) raphe nuclei early in the disease, but their relationship to brain changes is unclear. We investigated synaptic plasticity, neuronal activity, and functional magnetic resonance imaging (fMRI)-based brain connectivity in a PD-like mouse model with depressive phenotype. AAV-induced human α-Syn accumulation in raphe 5-HT neurons causes progressive synaptic pathology in interconnected brain regions. This is marked by lower MAP-2, PSD95 and higher SV2A, VAMP2, which are key to synaptic structure and function, as confirmed in human brain tissue samples. Abnormalities in Egr-1-dependent neuronal activity and region-specific differences in resting-state functional brain activity were also detected eight weeks post-AAV infusion, before neurodegeneration. This provides evidence for synaptic and fMRI markers associated with α-Syn pathology in emotional brain circuits, and has translational importance for identifying PD patients at risk for depression., This work was supported by MCIU/AEI/FEDER, UE grant (PID2019-105136RB-100, PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 to A.B.), and AGAUR 2021-SGR-01358, Catalan Government. CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM). We also thank the Spanish Stress Research Network, MCIN/AEI/10.13039/501100011033. U.S.S. is a recipient of a fellowship from the Non- Doctor Researcher Formation Pre-doctoral Program of Basque Government, Spain. U.A. is a recipient of a fellowship from the State Research Agency for the training of predoctoral research personnel (PREP2022-000676) associated to a generation of knowledge project (PID2022-141700OB-I00). The authors would like to thank the staff members of the Biobank of the Clinic Hospital Barcelona - IDIBAPS for their collaboration in the study., Peer reviewed